Alector, Inc.
Financials
Valuation Metrics
Alector, Inc.'s Market Cap is $205M. At end of 2025 it was $161M. Ranked #3021 of 3,121 in US market (top 97%), #1385 of 1,463 on NASDAQ (top 95%), #252 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 95%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $205M | US#3,021/3,121 Sec#252/266 |
| Revenue | $14M | US#2,826/3,121 Sec#169/266 |
| Net Income | $-118M | US—/3,121 Sec—/266 |
| Total Assets | $203M | US#2,991/3,121 Sec#245/266 |
| Net Assets | $-10M | US#2,928/3,121 Sec#244/266 |
| Employees | 103 | US#2,621/3,121 Sec#177/266 |
| Value | ||
| P/S | 14.82x | US#2,789/3,121 Sec#129/266 |
| FCF Yield | -77.12% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROA | -58.10% | US#3,015/3,121 Sec#228/266 |
| Op. Margin | -914.56% | US#2,827/3,121 Sec#165/266 |
| Revenue Growth | -82.91% | US#2,765/3,121 Sec#178/266 |
| Financial Health | ||
| Total Debt | $33M | US#2,686/3,121 Sec#172/266 |
| FCF | $-158M | US#2,730/3,121 Sec#183/266 |
| Cash | $60M | US#2,503/3,121 Sec#218/266 |
| Current Ratio | 5.26x | US#449/3,121 Sec#137/266 |
| Performance | ||
| 1Y Return | -37.29% | US#2,755/3,121 Sec#235/266 |
| 1M Return | -16.29% | US#2,871/3,121 Sec#229/266 |
| From 52W High | -45.59% | US#2,612/3,121 Sec#207/266 |
| 1Y MDD | -65.66% | US#2,897/3,121 Sec#230/266 |
| Trading | ||
| Volume | 916,004 shares | US#1,471/3,121 Sec#158/266 |
| Trading Value | $2M | US#2,936/3,121 Sec#250/266 |
| Per Share | ||
| EPS | $-1.06 | US—/3,121 Sec—/266 |
| BPS | $-0.09 | US—/3,121 Sec—/266 |
Company Info
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.